Alkylating Agents

A 52-year-old man with multiple myeloma is started on high-dose melphalan followed by autologous stem cell transplantation. Which is the most common acute hematological toxicity expected within the first 2–3 weeks post-transplantation?

A 52-year-old man with newly diagnosed multiple myeloma presents to the oncology clinic. He is planned for induction therapy with bortezomib and dexamethasone followed by high-dose melphalan with autologous stem cell transplantation. Before initiating melphalan, which investigation is most appropriate to assess the risk of treatment-related toxicity and guide dose modification?

Which of the following alkylating agents is a nitrogen mustard derivative that requires hepatic activation to form its active metabolite?

Which alkylating agent is most commonly associated with hemorrhagic cystitis as a dose-limiting toxicity, and what is the mechanism of this adverse effect?

A 52-year-old man with newly diagnosed multiple myeloma presents with bone pain and elevated serum creatinine. He is planned for induction chemotherapy. Which alkylating agent is the drug of choice for initial treatment of multiple myeloma in India?